Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, announces the ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

Chinese APT Salt Typhoon has been exploiting known vulnerabilities in Cisco devices in attacks on telecom providers in the US ...

Q4 2024 Earnings Conference Call February 14, 2025 3:00 AM ETCompany ParticipantsMasamichi Terabatake - Group President ...

NIHR Global Health Research Groups have been awarded funding under the programme’s Group 4 Call to deliver high-quality applied global health research and training in low and middle income countries ...

Britain has started supplying Ukraine with surface-to-air missiles that can be launched from shipping containers. The new ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

Cambridge-based anti-ageing biotech Shift Bioscience has set up a team and facilities in Canada to serve North America. The ...